Resources
Case Studies

How Dynamic Targeting is Transforming the Field

Two pharma teams replaced static call lists with weekly refreshed AI-prioritized call plans and outperformed their control groups.
25%
Field reps increased call volume by 25%.
15%
Brands expanded market reach by up to 15%.
49%
Prescription outcomes for pilot users were 49% better.

Project Overview

Company Profiles

Across the industry, teams are shifting away from rigid, static targeting cycles. This case study focuses on two companies that made that change by adopting ODAIA’s dynamic segmentation and targeting.

Company A Company B
Overview:
A midsize specialty pharma company with a broad US footprint focused on primary‑care treatment.
Overview:
An emerging biopharma company focused on respiratory diseases and a novel COPD treatment.
Therapeutic Area:
Immunology – focus on primary care
Therapeutic Area:
Respiratory disease
Territories Analyzed:
41 (nationwide US rollout)
Territories Analyzed:
5 (select US territories selected for pilot)
Project Type:
Full commercial launch
Project Type:
Pilot rollout
Drug Stage:
Established brand / mature product category
Drug Stage:
Launch product / emerging product

By leveraging AI-powered segmentation (PowerScores), real-time insights, and weekly refreshed curated call plans, these organizations experienced a new level of field productivity and strategic focus —proving that dynamic targeting isn’t just more efficient, it’s more effective.

Dynamic targeting leverages AI-powered prioritization to preserve market share, mitigate prescription decline, and drive measurable gains in call volume, market reach, and resource allocation across pharmaceutical field teams.

Proven Results: 

  • Field reps achieved 25% increase in call volume across multiple organizations & territory structures
  • Brands expanded market reach by up to 15% by identifying new high-potential HCP relationships
  • Prescription outcomes for pilot users were 49% better than the control group

The Challenge

Static Targeting in a Dynamic Market

Outdated Segmentation is Limiting the Field: Before implementing ODAIA, both companies relied on traditional, consultant-driven targeting approaches that couldn’t keep pace with therapidly evolving pharmaceutical marketplace.

  1. Static Lists: HCP segmentation was refreshed only semi-annually, meaning field reps were working with outdated evaluations for months at a time. This means reps lacked the ability to identify emerging opportunities outside their predetermined target lists.
  2. Limited Market Visibility: With call plans locked in months in advance, reps were limited in their ability to see behavioral changes and act on them. Those who attempt to manually correlate numerous dashboards and spreadsheets find different conclusions and can easily miss key insights hidden in a mountain of data points.
  3. Inefficient Resource Allocation: Static segmentation meant reps often spent valuable selling time on the wrong HCPs while missing chances to engage higher potential providers. They also spent tremendous time manually reviewing data sources and dashboards trying to consolidate the right information to plan their days.
Traditional Semi-Annual Targeting Approach Infographic

The Solution

ODAIA’s AI Platform and Dynamic Targeting

From Static Lists to Real-Time Intelligence: ODAIA transformed how both companies approached field planning, HCP segmentation, and execution through three core capabilities:

  1. AI-Driven PowerScores: By analyzing real-time commercial data, continuously monitoring changes in HCP activity trends, patient volumes, market movements, and engagement history, ODAIA generates a PowerScore for each HCP. These scores dynamically evaluate prescribers by potential and actual value.
  2. Weekly Refreshed Territory Call Plans: Reps working with ODAIA receive weekly prioritized call plans. These plans incorporate predictive insights, and territory specific opportunities, ensuring reps focus their efforts where they’ll have the greatest impact.
  3. Summarized Pre-Call Insights: By aggregating data and signals into insights, ODAIA reduces the burden placed on reps to correlate their own findings. HCP insights are presented in plain text with supporting data points, giving reps the confidence to engage their customers.
ODAIA Call Lists, PowerScores, and HCP Insights

The Results

Measurable Impact Across the Field

How Results Were Measured: The study included a detailed implementation and pilot phase, to ensure findings reflected genuine impact.

Key Performance Results Among Top Users

Pilot vs Control Group Comparison

Metric Company A
(41 Territories)
Company B
(5 Territories)
Call Volume Growth +24.8%(16,677 → 21,857 calls) +15.3%(2,784 → 3,261 calls)
Daily Call Increase (Per Rep) +1.68 calls/day/territory +0.93 calls/day/territory
New Market Reach/ Expansion +9.7%(593 new providers) +15%(122 new providers)
Field Activity & Engagement Resource reallocation to high-value HCPs Engagement optimized to most impactful HCPs
Mitigated Loss Analysis for Company B

The drug/ brand evaluated for Company B is a mature product in a competitive market experiencing overall prescription volume decline. Against this, ODAIA users demonstrated meaningful mitigation of market share loss compared to the control group.

Company B User Group Avg. Rx Rate of Decline vs. Control
ODAIA Power Users -3.8 Rx(Prescription referrals) 83% mitigated loss
ODAIA Pilot Users -11.6 Rx(Prescription referrals) 49% mitigated loss
Control Group -22.8 Rx(Prescription referrals) Baseline
Next Steps: Put Dynamic Targeting into Action

Ready to move beyond static HCP lists and see where dynamic targeting can have the most impact for your brand?

Get started with an Opportunity Analysis
Identify gaps in your current segmentation and uncover high‑potential HCPs your field team may be missing.

Pharma's Guide to Dynamic Segmentation & Targeting
Learn how leading pharma teams are operationalizing dynamic targeting across brands and territories.

Key Takeaways

Proven ROI Through Dynamic Targeting

ODAIA delivers measurable productivity gains through strategic HCP prioritization. Customer data demonstrates that field teams using dynamic targeting achieve higher call volumes, expanded market reach, and superior prescription outcomes.

For pharmaceutical companies still relying on static, semi-annually refreshed target lists, the opportunity cost is clear. In a dynamic market, dynamic targeting isn’t just an advantage, it’s essential for competitive field performance.

Next Steps: Put Dynamic Targeting into Action

Ready to move beyond static HCP lists and see where dynamic targeting can have the most impact for your brand?

Get started with an Opportunity Analysis
Identify gaps in your current segmentation and uncover high‑potential HCPs your field team may be missing.

Pharma's Guide to Dynamic Segmentation & Targeting
Learn how leading pharma teams are operationalizing dynamic targeting across brands and territories.

The Productivity Formula

Dynamic segmentation and targeting form the foundational layer that unites previously siloed teams—marketing, commercial leadership, field teams, and operations—while driving field productivity across the organization.

By consolidating disparate data into unified, continuously updating PowerScores, ODAIA creates the infrastructure for data-backed decision-making across the entire organization.

  1. Better Prioritization: ODAIA identifies highest-value HCPs for each strategic focus, eliminating guesswork and ensuring time is spent where it matters most.
  2. Time Savings: Streamlined planning and consolidated intelligence enable more dally customer interactions, breaking through the productivity potential of manual processes.
  3. Expanded Reach: Additional calls target new HCPs, growing market coverage and capturing opportunities competitors miss.
  4. Better Outcomes: Quality time with the right providers, at the right moment, drives superior prescription results.

More Customer Stories

Discover how innovative biopharmas are using ODAIA to drive brand growth, improve sales efficiency, and empower smarter decisions.